Cagrilintide represents the modern re-engineering of that idea: a lipidated, structurally modified amylin analogue stable enough for once-weekly dosing and active at both the amylin and calcitonin receptors
Results tend to be most noticeable when paired with calorie control, strength training, hydration, and regular movement
These clinical trial outcomes collectively highlight retatrutides multifaceted efficacy, paving the way for its potential role as a transformative therapy for metabolic diseases
Common side effects include: Injection site reactions mild pain, redness, swelling, or bruising at the injection site, typically resolving within a few days Headache usually transient and manageable with standard analgesia Nausea or dizziness particularly in the initial treatment phase Skin reactions including itching, mild rash, or acneiform eruptions Temporary urine discolouration red or orange urine is harmless and expected Diarrhoea or flushing usually mild and self-limiting In patients with severe megaloblastic anaemia, low potassium levels (hypokalaemia) may occur during initial intensive treatment, but this is uncommon in routine maintenance therapy
Once available, this section should include one current COA, one current HPLC, and one current MS document only
